Other substances

P9

A peptide-mimetic SARS-CoV-2 Spike inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
0
 Clinical trials

General information

P9 is a peptide-mimetic of the N-terminal helix of human ACE2 receptor. It strongly binds to SARS-CoV-2 Spike protein RBD and inhibits SARS-CoV-2 infection in vitro (Karoyan et al., 2021).

 

SALEEQYKTFLDKFMHELEDLLYQLSL-NH2

Supporting references

Link Tested on Impact factor Notes Publication date
Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection
Spike protein ACE2 Peptide In vitro 		Vero E6 cells; Calu-3 cells; SARS-CoV-2 clinical isolate PSL2020

Inhibited SARS-CoV-2 infection in Calu-3 cells with an IC50 of ca. 53 nM and an SI of ≥150. It displayed efficacy in Vero E6 cells, as well.

 Feb/12/2021

AI-suggested references

Link Publication date
Recombinant VLPs empower RBM peptides showing no immunogenicity in native SARS-COV-2 protein to elicit a robust neutralizing antibody response
Jan/21/2022
Export (.csv)